Clinical Trials Logo

Filter by:
NCT ID: NCT00318955 Completed - Conscious Sedation Clinical Trials

Post-Marketing Clinical Study to Assess Efficacy and Safety of Dexmedetomidine in Post-Operative Patients

Start date: November 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess efficacy and safety of dexmedetomidine at the time of extubation and after extubation, in patients requiring postoperative sedation in the ICU.

NCT ID: NCT00318786 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

Start date: April 2006
Phase: Phase 3
Study type: Interventional

This trial is conducted in Japan. This a clinical trial to study the efficacy and safety of three times a day BIAsp-70 compared to two times a day BIAsp-30 in subjects with type 2 diabetes.

NCT ID: NCT00318669 Completed - Social Phobia Clinical Trials

Social Anxiety Disorder Study Of Paroxetine

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).

NCT ID: NCT00316693 Completed - Clinical trials for Infections, Papillomavirus

Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

Start date: April 26, 2006
Phase: Phase 2
Study type: Interventional

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb). This infection may go away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. This study will evaluate the efficacy in prevention of persistent HPV-16 or HPV-18 cervical infection lasting at least 6 months, the immunogenicity and safety of GSK Biologicals HPV-16/18 vaccine (Cervarix TM ) over 24 months in Japanese adult women aged 20 - 25 years of age at study start. Approximately 1000 study subjects will either receive the HPV vaccine or a control vaccine (Hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00316238 Completed - Schizophrenia Clinical Trials

A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

Start date: April 2006
Phase: Phase 2
Study type: Interventional

To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia

NCT ID: NCT00312377 Completed - Lung Cancer Clinical Trials

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

ZODIAC
Start date: May 2006
Phase: Phase 3
Study type: Interventional

This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone. All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent. Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients. Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.

NCT ID: NCT00311740 Completed - Hypertension Clinical Trials

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated. The study aims to establish a dose response relationship for both monotherapies and the combinations. This study is being conducted in Japan.

NCT ID: NCT00311402 Completed - Clinical trials for Cerebrovascular Accident

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Start date: April 2006
Phase: Phase 3
Study type: Interventional

Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily

NCT ID: NCT00311129 Completed - Lymphoma, Low-Grade Clinical Trials

Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the antitumor effect and safety of fludarabine phosphate tablet in combination with rituximab in patient with indolent lymphoma.

NCT ID: NCT00311038 Completed - Clinical trials for Coronary Artery Disease

Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for multi-slice CT.